Xiangya Hospital, Central South University
Welcome,         Profile    Billing    Logout  
 1 Trial 
9 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ji, Li Li
NCT05607680: A Study of IBI362 in Participants With Obesity or Overweight

Completed
3
610
RoW
Placebo, IBI362
Innovent Biologics (Suzhou) Co. Ltd.
Obesity Or Overweight
08/23
04/24
NCT05093855: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
2
41
RoW
BDB-001 Injection
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa
08/23
08/23
NCT05103423: Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
1/2
50
RoW
BDB-001 Injection, Placebo
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa
07/23
07/23
Su, Juan
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults

Completed
3
286
RoW
Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis
Cutia Therapeutics(Wuxi)Co.,Ltd
Analgesia
08/23
10/23
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Active, not recruiting
3
330
RoW
SHR0302, Placebo
Reistone Biopharma Company Limited
Alopecia Areata
10/23
02/24
NCT06477237: Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting
3
400
RoW
HB0017 Q4W, HB0017 Q8W, placebo
Huabo Biopharm Co., Ltd.
Psoriasis
08/24
12/25
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis

Recruiting
3
552
RoW
ICP-332 Tablets, ICP-332 Placebo Tablets
Beijing InnoCare Pharma Tech Co., Ltd.
Atopic Dermatitis
11/26
12/26
NCT05531682: A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Completed
2
160
RoW
Placebo, HB0017, HB0017 dosing regimens
Huabo Biopharm Co., Ltd.
Plaque Psoriasis
05/23
01/24
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting
2
129
RoW
ICP-488 Tablets, ICP-488 Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Moderate to Severe Plaque Psoriasis
10/24
11/24

Download Options